| Literature DB >> 31544876 |
Ilokugbe Ettah1, Lorna Ashton2.
Abstract
In the last decade, a number of studies have successfully demonstrated Raman spectroscopy as an emerging analytical technique for monitoring antibody aggregation, especially in the context of drug development and formulation. Raman spectroscopy is a robust method for investigating protein conformational changes, even in highly concentrated antibody solutions. It is non-destructive, reproducible and can probe samples in an aqueous environment. In this review, we focus on the application and challenges associated with using Raman spectroscopy as a tool to study antibody aggregates.Entities:
Keywords: Raman spectroscopy; aggregation; antibody; protein structure
Year: 2018 PMID: 31544876 PMCID: PMC6640673 DOI: 10.3390/antib7030024
Source DB: PubMed Journal: Antibodies (Basel) ISSN: 2073-4468
Figure 1Schematic showing Rayleigh and Raman scattering processes (Stokes and anti-Stokes).
Figure 2Antibody Visible Raman spectrum of a monoclonal antibody (2 mg/mL) in aqueous solution at neutral pH excited with 532 nm laser line. Reproduced with permission from [17]. Copyright Elsevier (2007).
Figure 3(a) pH-induced changes in the Raman spectra of lactalalbumin from pH 0.8–7.8, (b) Shaded peaks in the Raman spectra of selected polypeptides and phenylalanine, assigned to specific protein structure: -α-helix (purple), β-sheet (yellow) and aromatic residues (blue) [44].
Raman peaks highlighting perturbation-induced structural changes.
| Peak (cm−1) | Spectral Change | Sample (Perturbation) | Structural Implication | Ref |
|---|---|---|---|---|
| Observable peaks at 510,531 & 545 in aggregate spectra vs. 531 for soluble Fc | Fc (unspecified) | GGG, TGG and TGT conformations present in aggregates vs mainly TGG in soluble Fc | [ | |
| Increased perturbation in (I510/540) for ND aggregates | Anti-streptavidin IgG1(temperature) | ND aggregation pathway showed greater sensitivity to this marker. | [ | |
| No change | rhuMab * (Lyophilisation) | - | [ | |
| Downshift | IVIG * (temperature) | Change in tertiary structure | [ | |
| Increased ratio | Rabbit IgG (concentration) | Increased molecular interaction | [ | |
| Increased/decreased intensity | IgG4 variant (temperature) | Less exposure to solvent/more exposure to solvent | [ | |
| Increased intensity | Rabbit IgG (storage) | Pre-aggregation | [ | |
| Broadening and shift to 1245 cm−1 | Human IgG1 (pH) | Formation of intermolecular β-sheet | [ | |
| Decreased ratio | IVIG (temperature) | Reduced hydrophobicity (change in tertiary structure) | [ | |
| Downshift | IVIG/temperature | Change in tertiary structure | [ | |
| Redshift | Anti-streptavidin IgG1(temperature) | Change in tertiary structure | [ | |
| Increased/decreased intensity | IgG4 variant (temperature) | Increase in intermolecular H-bonding of β-structure/Loss of bonding or loss of secondary structure | [ | |
| Decreased intensity | Human IgG1(pH) | Loss of Intramolecular β-sheet | [ | |
| Increased intensity | Human IgG1(pH) | Intermolecular β-sheet formation | [ |
* Recombinant humanized monoclonal antibody (rhuMab), intravenous immunoglobulin (IVIG).
Figure 4Raman and ROA spectra of IgG1 at pH 3 and 7 showing significant changes in the amide I and III regions for ROA spectra only. Reproduced with permission from [43]. Copyright Bentham Science Publishers Ltd. (2009).
Figure 5Background subtracted normalised ROA spectra of human monoclonal antibody IgG4(mAb1) (a) control (b) after 1-week thermal stress (c) after 2-week thermal stress (d) after 4-week thermal stress. Reproduced with permission from [65] Copyright © 2015 John Wiley & Sons, Ltd.